Table 1 PSV and EDV values of the OA after placebo, sildenafil and tadalafil administration

From: Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects

 

Baseline

1 h

4 h

8 h

12 h

24 h

36 h

48 h

PSV (cm/s) placebo no., 10 pts

69.0 (43.0–90.5)

60.5 (49.5–91.5)

65.5 (48.0–84.0)

69.5 (56.5–86.5)

73.5 (60.5–90.0)

65.5 (55.0–87.5)

60.0 (47.5–77.5)

65.0 (48.0–83.0)

EDV (cm/s) placebo no., 10 pts

22.0 (13.0–30.5)

19.5 (12.5–33.0)

22.5 (13.0–30.0)

25.0 (16.0–34.0)

23.0 (16–27.5)

23.5 (14.0–32.0)

25.5 (18.0–44.5)

23.0 (18.0–35.5)

PSV (cm/s) tadalafil (20 mg) no., 10 pts

63.0 (54.0–74.0)

106.5 (83.0–145.0)*

87.0 (80.0–105.0)*

93.5 (77.0–98.0)*

89.5 (81.0–100.0)*

84.0 (76.0–95.0)*

77.5 (63.0–100.0)**

63.0 (57.0–76.0)

EDV (cm/s) tadalafil (20 mg) no., 10 pts

27.5 (15.0–35.0)

43.5 (21.0–55.0)*

37.0 (19.0–46.0)*

40.0 (20.0–48.0)*

36.0 (17.0–47.0)**

36.0 (18.0–42.0)**

32.0 (16.0–38.0)

25.5 (14.0–32.0)

PSV (cm/s) sildenafil (100 mg) no., 10 pts

67.5 (44.5–88.5)

102.5 (74.5–120.0)**

69.5 (48.0–86.5)

65.0 (52.5–93.0)

66.0 (49.5–74)

70.0 (57.0–83.5)

70.5 (46.0–75–5)

71.0 (44–81.5)

EDV (cm/s) sildenafil (100 mg) no., 10 pts

19.5 (9.5–32.0)

31.5 (22.5–55.5)**

20.0 (11.0–24.5)

19.0 (16.5–25)

18.0 (11.5–22.0)

20.0 (14.5–24.5)

21.0 (15.0–29.0)

20.0 (16.0–27.5)

  1. Abbreviations: EDV, end-diastolic velocity; OA, ophthalmic artery; pts, patients; PSV, peak systolic velocity.
  2. *P<0.001 vs baseline; **P<0.01 vs baseline.
Back to article page